市場調查報告書 - 229833

挪威的體外診斷市場上投資機會,分析及預測

Norway In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018

出版商 Global Markets Direct
出版日期 2013年01月07日 內容資訊 英文 154 Pages
價格
挪威的體外診斷市場上投資機會,分析及預測 Norway In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018
出版日期: 2013年01月07日 內容資訊: 英文 154 Pages
簡介

本報告提供挪威的體外診斷市場主要資料和市場區隔及不同分類的收益,企業佔有率,流通佔有率等調查結果,再加上主要企業簡介,為您概述為以下內容。

目錄

1. 目錄

  • 1.1 表格一覽
  • 1.2 圖表一覽

2. 簡介

  • 2.1 關於本報告

3. 體外診斷 - 挪威

  • 3.1 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
  • 3.2 體外診斷, 挪威, 企業佔有率

4. 臨床化學檢驗 - 挪威

  • 4.1 臨床化學檢驗 整體收益 (實際成果及預測)
    • 4.1.1 臨床化學分析設備 收益 (實際成果及預測)
    • 4.1.2 尿液檢查 Analyzers 收益 (實際成果及預測)
  • 4.2 臨床化學檢驗 流通佔有率
  • 4.3 臨床化學檢驗, 挪威, 企業佔有率

5. 遺傳基因檢驗 - 挪威

  • 5.1 遺傳基因檢驗 整體收益 (實際成果及預測)
  • 5.2 遺傳基因檢驗 流通佔有率
  • 5.3 遺傳基因檢驗, 挪威, 企業佔有率

6. 血液檢驗 - 挪威

  • 6.1 血液檢驗 整體收益 (實際成果及預測)
    • 6.1.1 血液分析試劑 收益 (實際成果及預測)
    • 6.1.2 免疫血液學檢查 收益 (實際成果及預測)
    • 6.1.3 血液凝固檢查 收益 (實際成果及預測)
    • 6.1.4 簡易血液檢驗 收益 (實際成果及預測)
    • 6.1.5 血球計數器收益 (實際成果及預測)
  • 6.2 血液檢驗 流通佔有率
  • 6.3 血液檢驗, 挪威, 企業佔有率

7. 組織/細胞檢驗 - 挪威

  • 7.1 組織/細胞檢驗 整體收益 (實際成果及預測)
  • 7.2 組織/細胞檢驗 流通佔有率
  • 7.3 組織/細胞檢驗, 挪威, 企業佔有率

8. 免疫化學檢查 - 挪威

  • 8.1 免疫化學檢查 整體收益 (實際成果及預測)
    • 8.1.1 疾病專一 免疫化學檢查 收益 (實際成果及預測)
    • 8.1.2 藥物濫用/藥毒物檢驗 收益 (實際成果及預測)
    • 8.1.3 內分泌檢查 收益 (實際成果及預測)
    • 8.1.4 藥物治療監測 收益 (實際成果及預測)
    • 8.1.5 免疫化學分析儀 收益 (實際成果及預測)
  • 8.2 免疫化學檢查 流通佔有率
  • 8.3 免疫化學檢查, 挪威, 企業佔有率

9. 感染/免疫疾病檢驗 - 挪威

  • 9.1 感染/免疫疾病檢驗 整體收益 (實際成果及預測)
  • 9.2 感染/免疫疾病檢驗 流通佔有率
  • 9.3 感染/免疫疾病檢驗, 挪威, 企業佔有率

10. 微生物學培養檢驗 - 挪威

  • 10.1 微生物學培養檢驗 整體收益 (實際成果及預測)
  • 10.1.1 微生物檢驗設備 收益 (實際成果及預測)
  • 10.2 微生物學培養檢驗 流通佔有率
  • 10.3 微生物學培養檢驗, 挪威, 企業佔有率

11. 主要企業概要 - 挪威 體外診斷 市場

  • 11.1 F. Hoffmann-La Roche Ltd.
    • 11.1.1 企業概要
  • 11.2 Siemens Healthcare
    • 11.2.1 企業概要
  • 11.3 Abbott Laboratories
    • 11.3.1 企業概要
  • 11.4 Ortho-Clinical Diagnostics Inc.
    • 11.4.1 企業概要
  • 11.5 bioMerieux S.A.
    • 11.5.1 企業概要
  • 11.6 Beckman Coulter, Inc.
    • 11.6.1 企業概要
  • 11.7 Bio-Rad Laboratories, Inc.
    • 11.7.1 企業概要
  • 11.8 Sysmex Corporation
    • 11.8.1 企業概要
  • 11.9 Becton, Dickinson及Company
    • 11.9.1 企業概要
  • 11.10 Phadia AB
    • 11.10.1 企業概要
  • 11.11 Alere Inc.
    • 11.11.1 企業概要
  • 11.12 DiaSorin S.p.A
    • 11.12.1 企業概要
  • 11.13 Danaher Corporation
    • 11.13.1 企業概要
  • 11.14 DIAGNOSTICA STAGO, Inc.
    • 11.14.1 企業概要
  • 11.15 Thermo Fisher Scientific Inc.
    • 11.15.1 企業概要
  • 11.16 PerkinElmer, Inc.
    • 11.16.1 企業概要
  • 11.17 Qiagen N.V.
    • 11.17.1 企業概要
  • 11.18 Gen-Probe Incorporated
    • 11.18.1 企業概要
  • 11.19 Grifols, S.A.
    • 11.19.1 企業概要
  • 11.20 堀場製作所
    • 11.20.1 企業概要
  • 11.21 Immucor, Inc.
    • 11.21.1 企業概要
  • 11.22 Life Technologies Corporation
    • 11.22.1 企業概要
  • 11.23 Hologic, Inc.
    • 11.23.1 企業概要
  • 11.24 Cellestis Limited
    • 11.24.1 企業概要

12. 財務交易展望

  • 12.1 合作
    • 12.1.1 Skyline Diagnostics Enters Into Research Agreement With Clavis Pharma
    • 12.1.2 Biofortuna Enters Into 流通 Agreement With Abbott
    • 12.1.3 NorDiag Enters Into Agreement With Precision System Science

13. 附錄

  • 13.1 Global Markets Direct 調查方法
  • 13.2 調查對象的市場定義
    • 13.2.1 體外診斷
  • 13.3 二級研究
  • 13.4 主要研究
  • 13.5 資料的模式化
  • 13.6 預測
  • 13.7 專門委員會的驗證
  • 13.8 貨幣換算
  • 13.9 諮詢方式
  • 13.10 免責聲明

表格一覽

  • 表格 1: 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
  • 表格 2: 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎, 實際成果
  • 表格 3: 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎,預測
  • 表格 4: 體外診斷, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 5: 臨床化學檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 6: 臨床化學檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 7: 臨床化學分析設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 8: 臨床化學分析設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 9: 尿液檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 10: 尿液檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 11: 臨床化學檢驗, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 12: 臨床化學檢驗, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 13: 遺傳基因檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 14: 遺傳基因檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 15: 遺傳基因檢驗, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 16: 遺傳基因檢驗, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 17: 血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 18: 血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 19: 血液分析試劑, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 20: 血液分析試劑, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 21: 免疫血液學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 22: 免疫血液學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 23: 血液凝固檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 24: 血液凝固檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 25: 簡易血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 26: 簡易血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 27: 血球計數器, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 28: 血球計數器, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 29: 血液檢驗, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 30: 血液檢驗, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 31: 組織/細胞檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 32: 組織/細胞檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 33: 組織/細胞檢驗, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 34: 組織/細胞檢驗, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 35: 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 36: 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 37: 疾病專一 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 38: 疾病專一 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 39: 藥物濫用/藥毒物檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 40: 藥物濫用/藥毒物檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 41: 內分泌檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 42: 內分泌檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 43: 藥物治療監測, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 44: 藥物治療監測, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 45: 免疫化學分析儀, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 46: 免疫化學分析儀, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 47: 免疫化學檢查, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 48: 免疫化學檢查, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 49: 感染/免疫疾病檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 50: 感染/免疫疾病檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 51: 感染/免疫疾病檢驗, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 52: 感染/免疫疾病檢驗, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 53: 微生物學培養檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 54: 微生物學培養檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 55: 微生物檢驗設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 56: 微生物檢驗設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 57: 微生物學培養檢驗, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 58: 微生物學培養檢驗, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 59∼62: 體外診斷, 挪威, 交易內容詳細內容
  • 表格 63: 美金V.S.該地貨幣, 挪威, 平均實質匯率

圖表一覽

  • 圖 1: 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
  • 圖 2: 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎, 實際成果
  • 圖 3: 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎,預測
  • 圖 4: 體外診斷, 挪威, 企業佔有率 (%)
  • 圖 5: 臨床化學檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 6: 臨床化學檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 7: 臨床化學分析設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 8: 臨床化學分析設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 9: 尿液檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 10: 尿液檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 11: 臨床化學檢驗, 挪威, 企業佔有率 (%)
  • 圖 12: 遺傳基因檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 13: 遺傳基因檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 14: 遺傳基因檢驗, 挪威, 企業佔有率 (%)
  • 圖 15: 血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 16: 血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 17: 血液分析試劑, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 18: 血液分析試劑, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 19: 免疫血液學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 20: 免疫血液學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 21: 血液凝固檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 22: 血液凝固檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 23: 簡易血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 24: 簡易血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 25: 血球計數器, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 26: 血球計數器, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 27: 血液檢驗, 挪威, 企業佔有率 (%)
  • 圖 28: 組織/細胞檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 29: 組織/細胞檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 30: 組織/細胞檢驗, 挪威, 企業佔有率 (%)
  • 圖 31: 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 32: 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 33: 疾病專一 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 34: 疾病專一 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 35: 藥物濫用/藥毒物檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 36: 藥物濫用/藥毒物檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 37: 內分泌檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 38: 內分泌檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 39: 藥物治療監測, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 40: 藥物治療監測, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 41: 免疫化學分析儀, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 42: 免疫化學分析儀, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 43: 免疫化學檢查, 挪威, 企業佔有率 (%)
  • 圖 44: 感染/免疫疾病檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 45: 感染/免疫疾病檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 46: 感染/免疫疾病檢驗, 挪威, 企業佔有率 (%)
  • 圖 47: 微生物學培養檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 48: 微生物學培養檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 49: 微生物檢驗設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 50: 微生物檢驗設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 51: 微生物學培養檢驗, 挪威, 企業佔有率 (%)
  • 圖 52: Global Markets Direct 調查方法

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

TOC

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 9

2 Introduction 11

2.1 What is This Report About? 11

3 In Vitro Diagnostics In Norway 12

3.1 In Vitro Diagnostics, Norway, Overall Revenue ($m) , USD Constant, 2004-2018 12

3.2 In Vitro Diagnostics, Norway, Company Share (2010-2011) 18

4 Clinical Chemistry In Norway 20

4.1 Clinical Chemistry Overall Revenue, (2004-2018) 20

4.1.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 24

4.1.2 Urine Analysis, Revenue (2004-2018) 28

4.2 Clinical Chemistry Distribution Share (2010-2011) 32

4.3 Clinical Chemistry, Norway, Company Share (2010-2011) 33

5 Genetic Testing In Norway 35

5.1 Genetic Testing Overall Revenue, (2004-2018) 35

5.2 Genetic Testing Distribution Share (2010-2011) 39

5.3 Genetic Testing, Norway, Company Share (2010-2011) 40

6 Haematology In Norway 42

6.1 Haematology Overall Revenue, (2004-2018) 42

6.1.1 Haematology Reagents, Revenue , (2004-2018) 46

6.1.2 Immunohaematology, Revenue (2004-2018) 50

6.1.3 Haemostasis, Revenue (2004-2018) 54

6.1.4 Haematology Rapid Tests, Revenue (2004-2018) 58

6.1.5 Haematology Cell Counters, Revenue (2004-2018) 62

6.2 Haematology Distribution Share (2010-2011) 66

6.3 Haematology, Norway, Company Share (2010-2011) 67

7 Histology And Cytology In Norway 69

7.1 Histology And Cytology Overall Revenue, (2004-2018) 69

7.2 Histology And Cytology Distribution Share (2010-2011) 73

7.3 Histology And Cytology, Norway, Company Share (2010-2011) 74

8 Immuno Chemistry In Norway 76

8.1 Immuno Chemistry Overall Revenue, (2004-2018) 76

8.1.1 Disease Specific Immunochemistry, Revenue (2004-2018) 80

8.1.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 84

8.1.3 Endocrinology Tests, Revenue (2004-2018) 88

8.1.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 92

8.1.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 96

8.1.6 Immunochemistry Analyzers, Revenue (2004-2018) 100

8.2 Immuno Chemistry Distribution Share (2010-2011) 104

8.3 Immuno Chemistry, Norway, Company Share (2010-2011) 105

9 Infectious Immunology In Norway 107

9.1 Infectious Immunology Overall Revenue, (2004-2018) 107

9.1.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 111

9.2 Infectious Immunology Distribution Share (2010-2011) 115

9.3 Infectious Immunology, Norway, Company Share (2010-2011) 116

10 Microbiology Culture In Norway 118

10.1 Microbiology Culture Overall Revenue, (2004-2018) 118

10.1.1 Microbiology Analyzers, Revenue (2004-2018) 122

10.2 Microbiology Culture Distribution Share (2010-2011) 126

10.3 Microbiology Culture, Norway, Company Share (2010-2011) 127

11 Overview of Key Companies in Norway In Vitro Diagnostics Market 129

11.1 F. Hoffmann-La Roche Ltd. 129

11.1.1 Company Overview 129

11.2 Siemens Healthcare 129

11.2.1 Company Overview 129

11.3 Abbott Laboratories 129

11.3.1 Company Overview 129

11.4 Ortho-Clinical Diagnostics Inc. 130

11.4.1 Company Overview 130

11.5 bioMerieux S.A. 130

11.5.1 Company Overview 130

11.6 Beckman Coulter, Inc. 131

11.6.1 Company Overview 131

11.7 Sysmex Corporation 131

11.7.1 Company Overview 131

11.8 Bio-Rad Laboratories, Inc. 131

11.8.1 Company Overview 131

11.9 Becton, Dickinson and Company 132

11.9.1 Company Overview 132

11.10 Alere Inc. 132

11.10.1 Company Overview 132

11.11 Mindray Medical International Limited 133

11.11.1 Company Overview 133

11.12 Danaher Corporation 133

11.12.1 Company Overview 133

11.13 Qiagen N.V. 134

11.13.1 Company Overview 134

11.14 DiaSorin S.p.A 134

11.14.1 Company Overview 134

11.15 Diagnostica Stago, Inc. 135

11.15.1 Company Overview 135

11.16 Thermo Fisher Scientific Inc. 135

11.16.1 Company Overview 135

11.17 PerkinElmer, Inc. 136

11.17.1 Company Overview 136

11.18 Horiba, Ltd. 136

11.18.1 Company Overview 136

11.19 Gen-Probe Incorporated 137

11.19.1 Company Overview 137

11.20 Immucor, Inc. 137

11.20.1 Company Overview 137

11.21 Life Technologies Corporation 138

11.21.1 Company Overview 138

11.22 Grifols, S.A. 138

11.22.1 Company Overview 138

11.23 Cellestis Limited 139

11.23.1 Company Overview 139

11.24 Hologic, Inc. 139

11.24.1 Company Overview 139

12 Appendix 140

12.1 Global Markets Direct Research Methodology 140

12.2 Definitions of Markets Covered in the Report 141

12.2.1 In Vitro Diagnostics 141

12.3 Secondary Research 152

12.4 Primary Research 152

12.5 Models 153

12.6 Forecasts 153

12.7 Expert Panel Validation 153

12.8 Currency Conversion 154

12.9 Contact Us 154

12.10 Disclaimer 154

List of Tables

1.1 List of Tables

Table 1: In Vitro Diagnostics, Norway, Overall Revenue ($m) , USD Constant, 2004-2018 13

Table 2: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Constant, Historic, 2004-2011 15

Table 3: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 17

Table 4: In Vitro Diagnostics, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011 19

Table 5: Clinical Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 21

Table 6: Clinical Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 23

Table 7: Clinical Chemisty Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 25

Table 8: Clinical Chemisty Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 27

Table 9: Urine Analysis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 29

Table 10: Urine Analysis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 31

Table 11: Clinical Chemistry, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011 32

Table 12: Clinical Chemistry, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011 34

Table 13: Genetic Testing, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 36

Table 14: Genetic Testing, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 38

Table 15: Genetic Testing, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011 39

Table 16: Genetic Testing, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011 41

Table 17: Haematology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 43

Table 18: Haematology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 45

Table 19: Haematology Reagents, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 47

Table 20: Haematology Reagents, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 49

Table 21: Immunohaematology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 51

Table 22: Immunohaematology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 53

Table 23: Haemostasis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 55

Table 24: Haemostasis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 57

Table 25: Haematology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 59

Table 26: Haematology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 61

Table 27: Haematology Cell Counters, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 63

Table 28: Haematology Cell Counters, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 65

Table 29: Haematology, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011 66

Table 30: Haematology, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011 68

Table 31: Histology And Cytology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 70

Table 32: Histology And Cytology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 72

Table 33: Histology And Cytology, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011 73

Table 34: Histology And Cytology, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011 75

Table 35: Immuno Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 77

Table 36: Immuno Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 79

Table 37: Disease Specific Immunochemistry, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 81

Table 38: Disease Specific Immunochemistry, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 83

Table 39: Drugs of Abuse / Toxicology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 85

Table 40: Drugs of Abuse / Toxicology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 87

Table 41: Endocrinology Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 89

Table 42: Endocrinology Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 91

Table 43: Immunochemistry Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 93

Table 44: Immunochemistry Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 95

Table 45: Therapeutic Drug Monitoring, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 97

Table 46: Therapeutic Drug Monitoring, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 99

Table 47: Immunochemistry Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 101

Table 48: Immunochemistry Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 103

Table 49: Immuno Chemistry, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011 104

Table 50: Immuno Chemistry, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011 106

Table 51: Infectious Immunology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 108

Table 52: Infectious Immunology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 110

Table 53: Infectious Immunology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 112

Table 54: Infectious Immunology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 114

Table 55: Infectious Immunology, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011 115

Table 56: Infectious Immunology, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011 117

Table 57: Microbiology Culture, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 119

Table 58: Microbiology Culture, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 121

Table 59: Microbiology Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 123

Table 60: Microbiology Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 125

Table 61: Microbiology Culture, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011 126

Table 62: Microbiology Culture, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011 128

List of Figures

1.2 List of Figures

Figure 1: In Vitro Diagnostics, Norway, Overall Revenue ($m) , USD Constant, 2004-2018 12

Figure 2: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Constant, Historic, 2004-2011 14

Figure 3: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 16

Figure 4: In Vitro Diagnostics, Norway, Company Share (%), 2011 18

Figure 5: Clinical Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 20

Figure 6: Clinical Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 22

Figure 7: Clinical Chemisty Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 24

Figure 8: Clinical Chemisty Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 26

Figure 9: Urine Analysis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 28

Figure 10: Urine Analysis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 30

Figure 11: Clinical Chemistry, Norway, Company Share (%), 2011 33

Figure 12: Genetic Testing, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 35

Figure 13: Genetic Testing, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 37

Figure 14: Genetic Testing, Norway, Company Share (%), 2011 40

Figure 15: Haematology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 42

Figure 16: Haematology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 44

Figure 17: Haematology Reagents, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 46

Figure 18: Haematology Reagents, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 48

Figure 19: Immunohaematology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 50

Figure 20: Immunohaematology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 52

Figure 21: Haemostasis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 54

Figure 22: Haemostasis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 56

Figure 23: Haematology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 58

Figure 24: Haematology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 60

Figure 25: Haematology Cell Counters, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 62

Figure 26: Haematology Cell Counters, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 64

Figure 27: Haematology, Norway, Company Share (%), 2011 67

Figure 28: Histology And Cytology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 69

Figure 29: Histology And Cytology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 71

Figure 30: Histology And Cytology, Norway, Company Share (%), 2011 74

Figure 31: Immuno Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 76

Figure 32: Immuno Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 78

Figure 33: Disease Specific Immunochemistry, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 80

Figure 34: Disease Specific Immunochemistry, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 82

Figure 35: Drugs of Abuse / Toxicology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 84

Figure 36: Drugs of Abuse / Toxicology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 86

Figure 37: Endocrinology Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 88

Figure 38: Endocrinology Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 90

Figure 39: Immunochemistry Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 92

Figure 40: Immunochemistry Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 94

Figure 41: Therapeutic Drug Monitoring, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 96

Figure 42: Therapeutic Drug Monitoring, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 98

Figure 43: Immunochemistry Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 100

Figure 44: Immunochemistry Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 102

Figure 45: Immuno Chemistry, Norway, Company Share (%), 2011 105

Figure 46: Infectious Immunology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 107

Figure 47: Infectious Immunology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 109

Figure 48: Infectious Immunology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 111

Figure 49: Infectious Immunology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 113

Figure 50: Infectious Immunology, Norway, Company Share (%), 2011 116

Figure 51: Microbiology Culture, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011 118

Figure 52: Microbiology Culture, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018 120

Figure 53: Microbiology Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 122

Figure 54: Microbiology Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 124

Figure 55: Microbiology Culture, Norway, Company Share (%), 2011 127

Figure 56: Global Markets Direct Methodology 140

挪威的體外診斷市場上投資機會,分析及預測是由出版商Global Markets Direct在2013年01月07日所出版的。這份市場調查報告書包含154 Pages 價格從美金2500起跳。

Back to Top
;